Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have been assigned an average rating of “Buy” from the ten research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $28.00.

Several research analysts recently issued reports on the stock. BidaskClub upgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, June 14th. HC Wainwright set a $27.00 price target on shares of Lexicon Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $21.00 price target on shares of Lexicon Pharmaceuticals in a research note on Wednesday, April 5th. ValuEngine upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Finally, Citigroup Inc. increased their price target on shares of Lexicon Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, March 7th.

COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/06/20/lexicon-pharmaceuticals-inc-lxrx-given-consensus-recommendation-of-buy-by-analysts.html.

A number of hedge funds have recently added to or reduced their stakes in the stock. Old Mutual Global Investors UK Ltd. raised its stake in Lexicon Pharmaceuticals by 38.2% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 421,242 shares of the biopharmaceutical company’s stock worth $6,040,000 after buying an additional 116,513 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in Lexicon Pharmaceuticals by 33.3% in the first quarter. Candriam Luxembourg S.C.A. now owns 260,000 shares of the biopharmaceutical company’s stock worth $3,729,000 after buying an additional 65,000 shares in the last quarter. Boston Advisors LLC raised its stake in Lexicon Pharmaceuticals by 9.0% in the first quarter. Boston Advisors LLC now owns 32,655 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 2,695 shares in the last quarter. Macquarie Group Ltd. raised its stake in Lexicon Pharmaceuticals by 22.4% in the fourth quarter. Macquarie Group Ltd. now owns 68,431 shares of the biopharmaceutical company’s stock worth $946,000 after buying an additional 12,531 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Teachers Advisors LLC now owns 106,890 shares of the biopharmaceutical company’s stock worth $1,478,000 after buying an additional 27,378 shares in the last quarter.

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at 17.04 on Tuesday. The company’s market capitalization is $1.79 billion. Lexicon Pharmaceuticals has a 1-year low of $13.01 and a 1-year high of $19.62. The firm has a 50-day moving average of $15.45 and a 200 day moving average of $15.06.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.